Genomma Lab Internacional SAB de CV Class B LABB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LABB is a good fit for your portfolio.
News
-
Genomma Lab Internacional Announces Results for the First Quarter 2024
-
Genomma Lab Internacional S.A.B. de C.V. First Quarter 2024 Earnings Results Conference Call
-
GENOMMA LAB INTERNACIONAL ANNOUNCES SEVENTH DIVIDEND PAYMENT
-
Genomma Lab's ESG Rating Upgraded to A
-
Genomma Lab Internacional Reports Fourth Quarter & Full Year 2023 Results
-
EFFECTS OF ARGENTINA HYPERINFLATIONARY ACCOUNTING ON Q4 AND FULL YEAR 2023 RESULTS
Trading Information
- Previous Close Price
- MXN 14.64
- Day Range
- MXN 14.78–16.24
- 52-Week Range
- MXN 12.39–16.24
- Bid/Ask
- MXN 14.08 / MXN 16.10
- Market Cap
- MXN 15.24 Bil
- Volume/Avg
- 6.1 Mil / 3.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- 10.87
- Price/Sales
- 0.95
- Dividend Yield (Trailing)
- 5.19%
- Dividend Yield (Forward)
- 5.19%
- Total Yield
- 4.96%
Company Profile
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,975
- Website
- https://www.genommalab.com
Comparables
Valuation
|
Metric
|
LABB
|
BEVIDESA
|
GPROFUT
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.87 | 16.70 | 11.28 |
Price/Book Value | — | 4.14 | — |
Price/Sales | 0.95 | 0.51 | 1.35 |
Price/Cash Flow | 13.44 | — | 8.58 |
Price/Earnings
LABB
BEVIDESA
GPROFUT
Financial Strength
|
Metric
|
LABB
|
BEVIDESA
|
GPROFUT
|
|---|---|---|---|
Quick Ratio | 1.20 | 0.24 | 12.85 |
Current Ratio | 1.61 | 0.84 | 12.85 |
Interest Coverage | 3.52 | 1.90 | 10.34 |
Quick Ratio
LABB
BEVIDESA
GPROFUT
Profitability
|
Metric
|
LABB
|
BEVIDESA
|
GPROFUT
|
|---|---|---|---|
Return on Assets (Normalized) | 7.07% | 1.89% | 2.22% |
Return on Equity (Normalized) | 14.65% | 137.96% | 23.25% |
Return on Invested Capital (Normalized) | 11.47% | 11.46% | 19.08% |
Return on Assets
LABB
BEVIDESA
GPROFUT
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Jxklryzq | Qcdtcb | $69.8 Bil | |
ZTS
| Zoetis Inc Class A | Lkxhdtwml | Qwzv | $68.9 Bil | |
HLN
| Haleon PLC ADR | Nyrvkdq | Vyvgm | $37.7 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Knxdzrvf | Jqcj | $14.8 Bil | |
VTRS
| Viatris Inc | Qybnjlvf | Kvbgy | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Qfyltykv | Prl | $11.9 Bil | |
CTLT
| Catalent Inc | Vljxxmw | Cfnlgns | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Fkgvlzvbj | Gfb | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Myrpydky | Rbsr | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Bzcknwc | Lfpczz | $3.5 Bil |